GSK GSK RESULTS: Q2, Q2 sales GBP 8.409B vs. EST GBP 8.239B, Q2 ADJ operating profit GBP 2.800B vs. EST GBP 2.646B, Q2 ADJ EPS GBP 0.505 vs.
GSK GSK RESULTS: Q2, Q2 sales GBP 8.409B vs. EST GBP 8.239B, Q2 ADJ operating profit GBP 2.800B vs. EST GBP 2.646B, Q2 ADJ EPS GBP 0.505 vs. EST GBP 0.46, Q2 dividend GBP 0.17, GSK Earnings Notes:, Outlook FY core operating profit growth 7-9%, Outlook FY turnover growth 3-5%, Outlook FY core EPS growth 7-9%, Now expect 20+ phase III trial starts in 2026 (previously 10), GSK reaffirms its full-year 2026 guidance at constant exchange rates
GSK GSK RESULTS: Q2, Q2 sales GBP 8.409B vs.
EST GBP 8.239B, Q2 ADJ operating profit GBP 2.800B vs.
EST GBP 2.646B, Q2 ADJ EPS GBP 0.505 vs.
EST GBP 0.46, Q2 dividend GBP 0.17, GSK Earnings Notes:, Outlook FY core operating profit growth 7-9%, Outlook FY turnover growth 3-5%, Outlook FY core EPS growth 7-9%, Now expect 20+ phase III trial starts in 2026 (previously 10), GSK reaffirms its full-year 2026 guidance at constant exchange rates